On the other hand, while MSLN is a potential diagnostic/prognostic biomarker for PDAC which can contribute to tumor cell proliferation and invasion (36, 37), the glycopeptide of MSLN (MSLN-N388) did not demonstrate enough power to differentiate PDAC from nondiseased controls and pancreatitis. This evidence concerns the gene MSLN and neoplasm.